Table 3.
Comparison between the PKG+ and PKG− arms of primary and secondary endpoints.
| PKG+ (mean ± SD) | PKG− (mean ± SD) | P val | ΔSEM | 95% CI | |
|---|---|---|---|---|---|
| All participants’ final scores. PKG+ vs PKG− | |||||
| UPDRSa Total | 51.1 ± 14.8 | 57.4 ± 17.5 | 0.02* | 6.3 ± 2.6 | −1.3 to 11.4 |
| UPDRS III | 28.6 ± 8.0 | 33.2 ± 10.0 | 0.002* | 4.6 ± 1.4 | −1.8 to 7.4 |
| PDQ39b | 22.2 ± 13.6 | 25.6 ± 18.8 | 0.21 | 3.3 ± 2.6 | 1.8–8.4 |
| SENS PDc | 9.9 ± 4.6 | 11.4 ± 4.9 | 0.055 | 1.5 ± 0.8 | 1.5–3.0 |
| All participants. PKG+ (1st–last visit) vs PKG− (1st–final visit) | |||||
| UPDRS Total | 8.1 ± 13.6 | 3.8 ± 10.2 | 0.07 | 4.4 ± 1.9 | 0.6–8.4 |
| UPDRS III | 5.6 ± 8.2 | 1.5 ± 9.6 | 0.01* | 4.1 ± 1.4 | 1.3–6.9 |
| PDQ39 | 5.1 ± 10.6 | 4.6 ± 9.2 | 0.85 | 0.52 ± 1.6 | −2.6 to 3.6 |
| SENS PD | 1.1 ± 4.2 | 0.6 ± 9.3 | 0.49 | 0.52 ± 1.2 | −1.7 to 2.8 |
| Out of target at 1st visit. PKG+ (1st–last visit) vs PKG− (1st– last visit) | |||||
| UPDRS Total | 10.4 ± 12.7 | 3.1 ± 9.9 | 0.0019* | 7.3 ± 2.0 | 3.4–11.2 |
| UPDRS III | 7.1 ± 7.0 | 1.8 ± 9.9 | 0.0004* | 5.3 ± 1.5 | 2.4–8.3 |
| PDQ39 | 6.1 ± 9.8 | 4.0 ± 8.5 | 0.335 | 2.1 ± 1.6 | −1.1 to 5.2 |
| SENS PD | 1.7 ± 4.2 | 0.8 ± 9.1 | 0.26 | 0.92 ± 1.2 | −1.5 to 3.3 |
| Bradykinesia at 1st visit. PKG+ (1st– last visit) vs PKG− (1st–last visit) | |||||
| UPDRS Total | 12.7 ± 12.2 | 4.8 ± 10.3 | 0.0027* | 7.9 ± 2.2 | 3.5–12.3 |
| UPDRS III | 8.6 ± 8.3 | 2.6 ± 9.8 | 0.0008* | 6.0 ± 1.8 | 2.5–9.5 |
| PDQ39 | 6.8 ± 11.2 | 2.9 ± 8.8 | 0.065 | 3.9 ± 2.0 | 0.0–7.8 |
| SENS PD | 2.2 ± 4.5 | 0.4 ± 9.6 | 0.052 | 1.8 ± 1.5 | −1.1 to 4.7 |
Δ = difference. *P < 0.05.
aMovement Disorder Society Unified Parkinson’s Disease Rating Scale. bParkinson’s Disease Quality of Life 39 Questions. cSeverity of predominantly Non-dopaminergic Symptoms in Parkinson’s Disease.